drugset / Trial / NCT07047014
Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke
Phase 3
Recruiting
596 enrolled
Beijing Tiantan Hospital
Chinese Stroke Association · collabFirst Affiliated Hospital of Zhejiang University · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Results from recent several trials provided data showing limits to the effectiveness of thrombectomy for ischemic stroke due to medium vessel occlusions.The benefit-risk profile of thrombolysis for these patients has never been investigated. We initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of tenecteplase (0.25mg/kg, maximum dose 25mg) compared to standard medical care for patients with acute ischemic stroke due to medium vessel occlusion (MeVO) within 4.5 to 24 hours from symptom onset.
Timeline
- Start
- 2025-07-30
- Primary completion
- 2027-03-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenecteplase | Protein / enzyme biologic | 0.25 mg/kg | Intravenous |
| Comparator | Aspirin | Small molecule | — | — |
| Comparator | Clopidogrel | Small molecule | — | — |